Long-term proton pump inhibitors therapy and prevalence of hyperprolactinemia. a cross-sectional study in outpatient gastroenterology clinics
Journal of the Pakistan Medical Association · 2024
DOI: 10.47391/jpma.9541 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Journal of the Pakistan Medical Association, 2024. Verfasst von Muhammad Ashfaq und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, Pakistan. Hauptthemen laut MEDLINE: Proton Pump Inhibitors, Hyperprolactinemia, Prolactin. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To evaluate serum prolactin and macroprolactin levels in patients on long-term proton pump inhibitors therapy.
Method
The cross-sectional study was conducted from January 2018 to November 2019 after approval from the ethics review committee of the Commission on Science and Technology for Sustainable Development in the South University, Abbottabad, Pakistan. And comprised patients from two gastroenterology outpatient clinics in the Khyber Pakhtunkhwa province using proton pump inhibitors for >3 months either alone or in combination with either histamine receptor antagonists or prokinetics. Blood samples were collected from each patient for hormonal screening. Data was analysed using SPSS 25.
Results
Of the 166 patients, 101(60.8%) were females and 65(39.2%) were males. The overall mean age was 42.5±14.2 years, and the median serum prolactin level was 23.2ng/ml (interquartile range: 14.0-38.0ng/ml). There were 96(58%) patients with normoprolactinemia and 70(42%) with hypreprolactinemia. There were 19(11.4%) patients using combination therapy, while the rest were on proton pump inhibitors monotherapy. There was a significant increase in serum prolactin level with combination therapy compared to monotherapy (p=0.001). Pateints having treatment duration 11-20 months (p=0.006) and >40 months (p=0.001) were at high risk of developing hyperprolactinemia.
Conclusion
Long-term use of proton pump inhibitors could increase serum prolactin levels, and appropriate evaluation is essential for clinical management. Key Words: Proton pump inhibitors, Long-term therapy, Hyperprolactinemia, Omeprazole, Prolactin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, Pakistan.
- Department of Gastroenterology, MTI Ayub Medical Complex, Abbottabad, Pakistan.
- Department of Community Medicine, Ayub Medical College, Abbottabad, Pakistan.
Zitieren
APA
Ashfaq, M., Khan, A. N., Alkahraman, Y. M., & Haroon, M. Z. (2024). Long-term proton pump inhibitors therapy and prevalence of hyperprolactinemia. a cross-sectional study in outpatient gastroenterology clinics. Journal of the Pakistan Medical Association. https://doi.org/10.47391/jpma.9541
Vancouver
Ashfaq M, Khan AN, Alkahraman YM, Haroon MZ. Long-term proton pump inhibitors therapy and prevalence of hyperprolactinemia. a cross-sectional study in outpatient gastroenterology clinics. Journal of the Pakistan Medical Association. 2024. doi:10.47391/jpma.9541
BibTeX
@article{Ashfaq2024,
author = {Ashfaq, Muhammad and Khan, Adil Naseer and Alkahraman, Yasser Msa and Haroon, Muhammad Zeeshan},
title = {Long-term proton pump inhibitors therapy and prevalence of hyperprolactinemia. a cross-sectional study in outpatient gastroenterology clinics},
journal = {Journal of the Pakistan Medical Association},
year = {2024},
doi = {10.47391/jpma.9541}
}
EUVIMED